medigraphic.com
ISSN 1405-1699 (Print)
Órgano Oficial del Colegio Mexicano de Alergia, Asma e Inmunología Pediátrica y de la Asociación Latinoamericana de Pediatría

2017, Number 1

<< Back Next >>

Alerg Asma Inmunol Pediatr 2017; 26 (1)

Cannabinoids: from science to controversy

Huerta LJG, Ortega MJA, Vargas CE, Alvarado VIG

Language: Spanish
References: 16
Page: 16-20
PDF size: 262.93 Kb.


ABSTRACT

The subject of the medical use of marijuana has become controversial for our country. Cannabis is the most frequently used illicit substance in the world. The marijuana is considered a risk factor for consume other types of drugs, which becomes an epidemiological worldwide problem. Cannabis sativa contains 480 Cannabinoids compounds, and only 66 compounds cause different effects. The delta-9-te- trahidro-cannabinol is the main psychoactive compound which generates relaxation. The cannabidiol is the substance that mostly accumulates, even though this is not psychoactive. The functions of the endogenous cannabinoid is focused on different physiological processes mainly in the brain, immune system, respiratory and cardiovascular. The FDA has approved some cannabinoids as: nabilone and dronabinol with different indications. There are few studies that are methodologically structured and controlled therefore we continue with the need for studies methodologically well designed to help us to define the true therapeutic use of marijuana.


REFERENCES

  1. Comisión Nacional contra las Adicciones. El uso médico del cannabis ¿Tiene sustento Científico? 2014.

  2. Resumen ejecutivo. Informe mundial sobre las drogas 2013. Oficina de las Naciones Unidas contra la Droga y el Delito.

  3. Degenhardt L, Ferrari AJ, Calabria B, Hall WD et al. The global epidemiology and contribution of cannabis use and dependence to the global burden of disease: results from the GBD 2010 study. PLoS One. 2013; 8 (10): e76635.

  4. Encuesta Nacional de Adicciones 2011. Drogas ilícitas. 2012.

  5. Rodríguez-Reyes Y, Pérez-Padilla R. Efectos de la mariguana en el sistema respiratorio. Neumol Cir Torax. 2013; 72 (3): 194-196.

  6. Jácome RA. Cannabis medicinal. Medicina (Bogotá). 2014; 36 (4): 293-297.

  7. Benson MK, Bentley AM. Lung disease induced by drug addiction. Thorax. 1995; 50: 1125-1127.

  8. Di Marzo V, Melck D, Bisogno T, De Petrocellis L. Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action. Trends Neurosci. 1998; 21 (12): 521-528.

  9. Fernández-Ruiz J, Lastres-Becker I, Cabranes A, González S, Ramos JA. Endocannabinoids and basal ganglia functionality. Protaglandins Leukot Essent Fatty Acids. 2002; 66: 257-267.

  10. Piomelli D, Giuffrida A, Calignano A, Rodriguez de Fonseca F. The endocannabinoid system as a target for therapeutic drugs. Trends Pharmacol Sci. 2000; 21: 218-224.

  11. Parolaro D. Presence and functional regulation of cannabinoid receptors in immune cells. Life Sci. 1999; 65: 637-644.

  12. Fraguas-Sánchez AI, Fernández-Carballido AM, Torres-Suárez AI. Cannabinoides: una prometedora herramienta para el desarrollo de nuevas terapias. An Real Acad Farm. 2014; 80 (3): 555-577.

  13. Ramírez-Coronel M. Entrará a México medicamento con cannabis. El Economista; Sep.: 2015. [Internet] Disponible en: http://eleconomista.com.mx/columnas/salud-negocios/2015/09/08/entrara-mexico-medicamento-cannabis

  14. Maldonado LB, Avellán AJM. Síndrome de Lennox-Gastaut. Residente. 2009; IV (2): 56-66.

  15. http://www.galenusrevista.com/Cannabis-o-cannabinoides.html

  16. Alvear T, Gonzalo. Reflections about medicinal and recreational use of marijuana and its effects on the respiratory system. Rev Chil Enf Resp. 2015; 31 (3): 160-169.




2020     |     www.medigraphic.com